SOCS3 and non-small cell lung carcinoma: Thus, JAK–STAT pathway inhibitors could be a potential method in NSCLC therapy either alone or in combination with EGFR-TKIs.45 M. Li and his team studied the role of suppressor of cytokine signaling 3 (SOCS3) and miR-410 in regulating proliferation in NSCLC.